Biotech | May 16, 2022
Inmagene receives USFDA IND clearance for a third-generation BTK inhibitor
It is developing the drug candidate to potentially treat immunological diseases
It is developing the drug candidate to potentially treat immunological diseases
In clinical trials, treatment proved more effective than other therapies evaluated
It is a new class of drug that treats uncontrolled LDLCholesterol, despite the use of a maximum tolerated dose of statins
A seasoned professional, he will lead the strategy and business operations of Cadila’s branded prescriptions pharma business
East Syracuse site to serve as the LOTTE Center for North America Operations for LOTTE’s biologics contract development and manufacturing organization (CDMO) business
Capabilities include the latest in sterile lyophilization and liquid filling technology to support global pharmaceutical supply chain, keeping pace with industry trends
The pharma companies will bring quality products at competitive prices to consumers in Oman and help bring down the cost of healthcare
Candle Partners, an investment banking & advisory service for M&A among others, has closed many deals in the healthcare space. Ankit Poddar, Director, Candle Partners spoke to Thomas C Thottathil, Editor, Indianpharmapost.com about the prospects for the industry.
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
The unit is an oral manufacturing facility at Jedcherla, Hyderabad
Subscribe To Our Newsletter & Stay Updated
